General Information of the Compound
Compound ID |
CP0002211
|
||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Compound Name |
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
Show/Hide
|
||||||||||||||||||
Synonyms |
5-(5-FLUORO-2-OXO-1,2-DIHYDRO-INDOL-3-YLIDENEMETHYL)-2,4-DIMETHYL-1H-PYRROLE-3-CARBOXYLIC ACID (2-DIETHYLAMINO-ETHYL)-AMIDE
KS-5022
N-(2-diethylaminoethyl)-5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
N-[2-(diethylamino)ethyl]-5-[(Z)-(5-fluoro-2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]-2,4-dimethyl-1H-pyrrole-3-carboxamide
PDGF TK antagonist
PMID28460551-Compound-2
SU 11248
SU-11248
SU-11248J
SU-12662
SU11248
Su-011248
Sunitanib
Sunitinib
Sunitinib (INN)
Sunitinib (Pan-TK inhibitor)
Sunitinib (free base)
Sunitinibum
Sutent
Sutent (TN)
Show/Hide
|
||||||||||||||||||
Structure |
|
||||||||||||||||||
Formula |
C22H27FN4O2
|
||||||||||||||||||
Molecular Weight |
398.482
|
||||||||||||||||||
Canonical SMILES |
CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C
Show/Hide
|
||||||||||||||||||
InChI |
InChI=1S/C22H27FN4O2/c1-5-27(6-2)10-9-24-22(29)20-13(3)19(25-14(20)4)12-17-16-11-15(23)7-8-18(16)26-21(17)28/h7-8,11-12,25H,5-6,9-10H2,1-4H3,(H,24,29)(H,26,28)/b17-12-
Show/Hide
|
||||||||||||||||||
InChIKey |
WINHZLLDWRZWRT-ATVHPVEESA-N
|
||||||||||||||||||
CAS |
326914-13-0
557795-19-4
|
||||||||||||||||||
Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
PubChem ID | |||||||||||||||||||
ChEMBL ID | |||||||||||||||||||
DrugBank ID |
Map of Molecular Bioactivity Related to the Compound
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT00922, Epidermal growth factor receptor
Protein ID: PT01201, Hepatocyte growth factor receptor
Protein ID: PT01008, Macrophage colony-stimulating factor 1 receptor
Protein ID: PT00888, Mast/stem cell growth factor receptor Kit
Cell-based Assay
Biochemical Assays
Protein ID: PT01092, Platelet-derived growth factor receptor alpha
Protein ID: PT00844, Platelet-derived growth factor receptor beta
Cell-based Assay
Protein ID: PT03002, Potassium voltage-gated channel subfamily D member 3
Protein ID: PT00897, Potassium voltage-gated channel subfamily H member 2
Protein ID: PT00951, Proto-oncogene tyrosine-protein kinase receptor Ret
Protein ID: PT01204, Receptor-type tyrosine-protein kinase FLT3
Cell-based Assay
Biochemical Assays
Protein ID: PT01105, Sodium channel protein type 5 subunit alpha
Protein ID: PT03795, Solute carrier family 22 member 1
Protein ID: PT00864, Vascular endothelial growth factor receptor 2
Cell-based Assay
Biochemical Assays
Protein ID: PT01102, Voltage-dependent L-type calcium channel subunit alpha-1C
Cell Viability or Cytotoxicity Assay
Clinical Information about the Compound
Drug 1 ( Sunitinib )
Drug Name | Sunitinib | ||
---|---|---|---|
Company | Pfizer | ||
Indication | |||
Target(s) |
Vascular endothelial growth factor receptor 2 (KDR)
Modulator
|